Credo Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.50 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.13 Cr
as on 23-10-2024
- Company Age 11 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.10 Cr
as on 23-10-2024
- Revenue -64.84%
(FY 2023)
- Profit -65.96%
(FY 2023)
- Ebitda -1152.41%
(FY 2023)
- Net Worth -14.14%
(FY 2023)
- Total Assets -45.95%
(FY 2023)
About Credo Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.50 Cr and a paid-up capital of Rs 1.13 Cr.
The company has closed loans amounting to ₹3.10 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Siva Aluru, Aluru Krishna, Kandru Madhavarao, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232TG2013PTC089087
- Company No.
089087
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jul 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Credo Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Siva Aluru  | Director | 01-Jul-2019 | Current |
| Aluru Krishna | Director | 23-Jul-2013 | Current |
| Kandru Madhavarao | Director | 23-Jul-2013 | Current |
| Aluru Narmada | Director | 24-Mar-2014 | Current |
Financial Performance of Credo Pharma.
Credo Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 64.84% decrease. The company also saw a substantial fall in profitability, with a 65.96% decrease in profit. The company's net worth observed a substantial decline by a decrease of 14.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Credo Pharma?
Unlock access to Credo Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Credo Life Sciences Private LimitedActive 10 years 5 monthsSiva Aluru, Aluru Krishna and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 Jun 2014 | ₹3.10 Cr | Satisfied |
How Many Employees Work at Credo Pharma?
Unlock and access historical data on people associated with Credo Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Credo Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Credo Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
